Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.

Brokerages have set a one year consensus price objective of $34.00 for the company, according to Zacks. Zacks has also assigned Deciphera Pharmaceuticals an industry rank of 108 out of 265 based on the ratings given to related companies.

Several equities analysts have recently issued reports on the company. Nomura assumed coverage on Deciphera Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $57.00 price target for the company. Piper Jaffray Companies assumed coverage on Deciphera Pharmaceuticals in a research report on Monday. They issued an “overweight” rating and a $35.00 price target for the company. Instinet assumed coverage on Deciphera Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $57.00 price target for the company. JMP Securities assumed coverage on Deciphera Pharmaceuticals in a research report on Monday. They issued an “outperform” rating and a $38.00 price target for the company. Finally, J P Morgan Chase & Co assumed coverage on Deciphera Pharmaceuticals in a research report on Monday. They issued an “overweight” rating and a $30.00 price target for the company.

Deciphera Pharmaceuticals (NASDAQ DCPH) traded down 2.12% during mid-day trading on Tuesday, hitting $20.35. 118,718 shares of the stock traded hands. The firm’s 50-day moving average is $21.24 and its 200 day moving average is $21.24. The firm’s market cap is $649.67 million. Deciphera Pharmaceuticals has a 52-week low of $16.11 and a 52-week high of $24.50.

TRADEMARK VIOLATION NOTICE: “Zacks: Deciphera Pharmaceuticals, Inc. (DCPH) Given $34.00 Consensus Price Target by Brokerages” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/24/zacks-deciphera-pharmaceuticals-inc-dcph-given-34-00-consensus-price-target-by-brokerages.html.

In other Deciphera Pharmaceuticals news, major shareholder New Leaf Venture Management Ii acquired 375,000 shares of Deciphera Pharmaceuticals stock in a transaction that occurred on Monday, October 2nd. The stock was bought at an average cost of $17.00 per share, for a total transaction of $6,375,000.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Get a free copy of the Zacks research report on Deciphera Pharmaceuticals (DCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.